RT Journal Article
SR Electronic
T1 Improved delivery of fenoterol plus ipratropium bromide using Respimat® compared with a conventional metered dose inhaler
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 225
OP 232
DO 10.1183/09031936.01.17202250
VO 17
IS 2
A1 J. Goldberg
A1 E. Freund
A1 B. Beckers
A1 R. Hinzmann
YR 2001
UL http://erj.ersjournals.com/content/17/2/225.abstract
AB Asthma can be effectively treated by the use of bronchodilator therapies administered by inhalation. The objective of this study was to describe the dose-response relationship of combined doses of fenoterol hydrobromide (F) and ipratropium bromide (I) (F/I) delivered via Respimat®, a soft mist inhaler, and to establish the Respimat® dose which is as efficacious and as safe as the standard marketed dose of F/I (100/40 µg) which is delivered via a conventional metered dose inhaler (MDI).In a double-blind (within device) cross-over study with a balanced incomplete block design, 62 patients with stable bronchial asthma (mean forced expiratory volume in one second (FEV1) 63% predicted) were randomized at five study centres to receive five out of eight possible treatments: placebo, F/I 12.5/5, 25/10, 50/20, 100/40 or 200/80 µg delivered via Respimat®; F/I 50/20 or 100/40 µg delivered via MDI.Pulmonary function results were based on the per-protocol dataset, comprising 47 patients. All F/I doses produced greater increases in FEV1 than placebo. A log-linear dose-response was obtained for the average increase in FEV1 up to 6 h (AUC0–6 h) and peak FEV1 across the dose range administered by Respimat®. Statistically, therapeutic equivalence was not demonstrated between any F/I dose administered by Respimat® compared with the MDI. However 12.5/5 and 25/10 µg F/I administered via Respimat® were closest (slightly superior) to the F/I dose of 100/40 µg delivered via MDI. Pharmacokinetic data from 34 patients indicated a two-fold greater systemic availability of both drugs following inhalation by Respimat® compared to MDI. In general, the active treatments were well tolerated and safe with regard to vital signs, electrocardiography, laboratory parameters and adverse events.In conclusion, combined administration of fenoterol hydrobromide and ipratropium bromide via Respimat®, is as effective and as safe as higher doses given via a metered dose inhaler.